Table 3.
Characteristics of alive patients at the time of data analysis.
| Patient | Age/Sex * | ECOG * | BRAF Status | LDH * | MBM | LM Symptoms | Method of Diagnosis | Radiology | Treatment Prior to LM Diagnosis | Time from Primary Melanoma to LM Diagnosis | Time from Metastatic Melanoma to LM Diagnosis | Systemic Treatment Sequence Post LM Diagnosis | Radiotherapy | Time from LM Diagnosis to Last FU | Severe AEs | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 M | 0 | WT | N | Yes | No | MRI | Pachy/leptomeningeal enhancement | None | 16 years | 2 months | NIVO+IPI | SRS and WBRT | 48 months | Radio necrosis | CR |
| 2 | 52 F | 0 | WT | N | Yes | No | MRI | Nodular leptomeningeal enhancement | None | 9 months | None | NIVO+IPI | SRS | 45 months | Immune-related grade 4 eosinophilic fasciitis like toxicity | CR |
| 3 | 69 M | 0 | WT | N | Yes | No | MRI | Nodular leptomeningeal enhancement | DCZ | None | 3 months | 1st: IPI 2nd: NIVO 3rd: NIVO + MEK inh |
SRS | 64 months | Immune-related grade 3 pulmonary toxicity | CR No treatment since 26 months |
| 4 | 58 M | 0 | WT | N | Yes | No | MRI | Nodular leptomeningeal enhancement | IPI | 14 months | 6 months | NIVO | SRS | 67 months | None | CR No treatment since 22 months |
| 5 | 57 F | 1 | MT | N | Yes | No | MRI | Nodular leptomeningeal enhancement | BRAF inh | 46 months | 10 months | 1st: PEMBRO 2nd: BRAF inh + MEK inh |
SRS | 64 months | None | CR Already treated with BRAF and MEK inh |
* At LM diagnosis; M: male; F: female; N: normal; ECOG: Eastern Cooperative Oncology Group; WT: wild-type; MT: mutant; MBM: melanoma brain metastases; LM leptomeningeal disease; MRI: magnetic resonance imaging; DCZ: dacarbazine; NIVO: nivolumab; IPI: ipilimumab; PEMBRO: pembrolizumab; inh: inhibitors; SRS: stereotaxic radiosurgery; WBRT: whole brain radiotherapy; AEs: adverse events; FU: follow-up; CR: complete response.